返回排名列表

Surgery Partners, Inc. (SGRY)

NEUTRAL
HealthcareMedical Care FacilitiesUnited States

基本面

54

价格

$13.99

市值

$1.90B

第一部分 · 这家公司值多少

概览

Surgery Partners, Inc., together with its subsidiaries, owns and operates a network of surgical facilities and ancillary services in the United States. The company provides ambulatory surgery centers and surgical hospitals that offer non-emergency surgical procedures in various specialties, including orthopedics and pain management, ophthalmology, gastroenterology, and general surgery. It offers emergency departments; ancillary services such as physician practices and diagnostic testing; multi-specialty physician practices; urgent care facilities; and anesthesia services. In addition, it offers single- and multi-specialty facilities. Surgery Partners, Inc. was founded in 2004 and is headquartered in Brentwood, Tennessee.

No editorial profile for this company yet

Direct competitors

Who this company fights with for the same customers

No editorial profile for this company yet

No competitor list for this company yet.

资产负债表与流动性

营收

$3.37B

最近12个月(截至2026/6/30)

净利润

$-89M

最近12个月(截至2026/6/30)

自由现金流

$196M

股东权益合计

$1.71B

负债合计

$4.99B

流动比率

1.95

利息覆盖率

-

债务/EBITDA

7.18

每股收益

营收与净利润

自由现金流

收入构成

历史财务表

利润率变化

债务变化

债务负担有多重

增长一览表

增长 — 营业收入

公允价值估算

General case合理估值

公允价值

$17.17

当前价格

$13.99

安全边际

+18.5%

公允价值区间

$14.82 - $19.53

估算方法

Analyst price target:$18.73
Discounted cash flow (DCF):$17.06
Earnings multiple (P/E):Not enough data to compute it
Graham growth formula:Not enough data to compute it
Earnings power value (EPV):$11.29
Justified P/B:Not enough data to compute it
Dividend discount (Gordon):Not enough data to compute it
P/FFO, funds from operations:Not enough data to compute it
Mid-cycle earnings:$70.60
Revenue multiple:Not enough data to compute it
分析师共识:强力买入 (14B / 4H / 0S)
最近财报超预期:+68.07%

估值指标

市盈率(P/E)

-

ROE

-4.5%

市净率(P/B)

1.09

P/FCF

9.74

毛利率

-

ROIC

4.1%

盈利能力雷达图

Value Creation (Economic Moat)

ROIC

4.1%

WACC

4.9%

ROIC − WACC

-0.9 pp

ROIC is roughly in line with the cost of capital — the company is barely covering its capital cost.

基本面分析标准

通过(12)

  • P/FCF 9.74
  • P/B Ratio 1.09
  • Debt/Equity ratio
  • Operating Margin 11.4%
  • Positive Free Cash Flow
  • Current Ratio
  • Revenue Growth 5Y 12.2%
  • Analyst Consensus 78% Buy
  • Earnings Surprise avg 14.8%
  • Share Dilution 1.0%
  • Net Margin Trend -2.6% vs -5.6%
  • Piotroski F-Score 5/9

未通过(9)

  • EPS shows upward trend
  • Price CAGR -0.87%
  • ROIC 4.1%
  • CapEx intensity
  • Debt/EBITDA
  • Return on Tangible Assets
  • Low reliance on intangibles
  • DCF valuation (Fairly valued)
  • ROE -5.3%

不可用(6)

  • Gross Margin NaN%
  • Dividend Payout NaN%
  • Interest Coverage
  • Price below Graham Number
  • PEG Ratio (need PE > 0 and growth > 0)
  • Earnings Quality (OCF/Net Income)

Piotroski F-评分

5/9

信号混杂:部分领域需关注

score
criteria

盈利质量

-

低质量:需深入审查会计处理

股权稀释

1.0%

股份数量稳定

公司治理

管理团队

姓名职位年龄
Mr. J. Eric EvansCEO & Director48
Mr. David T. Doherty CPAExecutive VP & CFO53
Ms. Jennifer B. Baldock J.D.Executive VP and Chief Administrative & Development Officer54
Ms. Marissa A. BrittenhamExecutive VP & Chief Strategy Officer40
Mr. W. Trent WebbDivision President South45
Mr. Justin R. OppenheimerExecutive VP & COO40
Mr. Jon FredricksonSenior VP & Chief Information Officer-
Ms. Roxanne WomackSenior VP & Chief Compliance Officer-
Mr. Spencer ClarkGeneral Counsel & Senior VP-
Ms. Danielle BurkhalterExecutive VP & Chief Human Resources Officer40

审计风险

9

董事会风险

6

薪酬风险

4

股东权利风险

8

第二部分 · 价格与买入时机

这一部分不判断公司是否值得拥有:它帮助你在基本面说服你之后,选择何时买入。包含:技术分析、潜力、历史回撤、Gamma 敞口。

Latest News

Recent headlines for SGRY, sourced from Markets Gazette.

  • 3/3/2026NEGATIVE
    Surgery Partners Stock Hits 52-Week Low - Here's Why

    Markets Gazette reports a significant downturn for Surgery Partners, whose shares (SGRY) hit a new 52-week low in premarket trading. The decline was triggered by the release of financial results that fell short of analysts' expectations. Furthermore, the company provided a cautious outlook for 2026, fueling investor concerns regarding future growth and profitability. This development suggests downward pressure on the stock, with the market reacting negatively to both current performance and near-term prospects. Investors should closely monitor the evolution of the company's strategy and upcoming reports to assess any signs of recovery.

  • 2/23/2026NEGATIVE
    Surgery Partners Stock Down 39% as One Fund Slashes Stake by $19 Million

    Shares of Surgery Partners, a healthcare firm operating a national network of surgical centers, plummeted by a staggering 39%. The sharp decline was triggered by news that a major investment fund slashed its stake in the company, selling off shares worth $19 million. Such a substantial divestment by an institutional investor is a significant red flag for the market, often interpreted as a loss of confidence in the company's future prospects or valuation. This large-scale sell-off has created immense downward pressure on the stock, reflecting widespread investor concern. Traders will now be closely watching for any follow-up from the company or further signs of institutional selling to gauge the underlying reasons for the fund's exit.

via Markets Gazette